Diabetes  ||| S:0 E:9 ||| JJ
care  ||| S:9 E:14 ||| NN
in  ||| S:14 E:17 ||| IN
a  ||| S:17 E:19 ||| DT
predominantly  ||| S:19 E:33 ||| JJ
Native  ||| S:33 E:40 ||| NNP
Hawaiian  ||| S:40 E:49 ||| NNP
and  ||| S:49 E:53 ||| CC
Pacific  ||| S:53 E:61 ||| NNP
Islander  ||| S:61 E:70 ||| NNP
outpatient  ||| S:70 E:81 ||| NN
population  ||| S:81 E:92 ||| NN
Racial  ||| S:92 E:99 ||| JJ
differences  ||| S:99 E:111 ||| NNS
in  ||| S:111 E:114 ||| IN
diabetes  ||| S:114 E:123 ||| JJ
care  ||| S:123 E:128 ||| NN
and  ||| S:128 E:132 ||| CC
outcomes ||| S:132 E:140 ||| NNS
,  ||| S:140 E:142 ||| ,
particularly  ||| S:142 E:155 ||| RB
among  ||| S:155 E:161 ||| IN
African  ||| S:161 E:169 ||| NNP
Americans  ||| S:169 E:179 ||| NNPS
and  ||| S:179 E:183 ||| CC
Hispanics ||| S:183 E:192 ||| NNPS
,  ||| S:192 E:194 ||| ,
have  ||| S:194 E:199 ||| VBP
been  ||| S:199 E:204 ||| VBN
well-recognized ||| S:204 E:219 ||| JJ
.  ||| S:219 E:221 ||| .
The  ||| S:221 E:225 ||| DT
goal  ||| S:225 E:230 ||| NN
of  ||| S:230 E:233 ||| IN
this  ||| S:233 E:238 ||| DT
study  ||| S:238 E:244 ||| NN
was  ||| S:244 E:248 ||| VBD
to  ||| S:248 E:251 ||| TO
evaluate  ||| S:251 E:260 ||| VB
the  ||| S:260 E:264 ||| DT
quality  ||| S:264 E:272 ||| NN
of  ||| S:272 E:275 ||| IN
diabetes  ||| S:275 E:284 ||| JJ
care ||| S:284 E:288 ||| NN
,  ||| S:288 E:290 ||| ,
using  ||| S:290 E:296 ||| VBG
nationally  ||| S:296 E:307 ||| RB
recognized  ||| S:307 E:318 ||| VBN
standards  ||| S:318 E:328 ||| NNS
of  ||| S:328 E:331 ||| IN
care ||| S:331 E:335 ||| NN
,  ||| S:335 E:337 ||| ,
in  ||| S:337 E:340 ||| IN
a  ||| S:340 E:342 ||| DT
multispecialty ||| S:342 E:356 ||| NN
,  ||| S:356 E:358 ||| ,
hospital-based  ||| S:358 E:373 ||| JJ
clinic  ||| S:373 E:380 ||| NN
that  ||| S:380 E:385 ||| WDT
cares  ||| S:385 E:391 ||| VBZ
for  ||| S:391 E:395 ||| IN
a  ||| S:395 E:397 ||| DT
predominantly  ||| S:397 E:411 ||| JJ
Native  ||| S:411 E:418 ||| NNP
Hawaiian  ||| S:418 E:427 ||| NNP
and  ||| S:427 E:431 ||| CC
Pacific  ||| S:431 E:439 ||| NNP
Islander  ||| S:439 E:448 ||| NNP
population ||| S:448 E:458 ||| NN
.  ||| S:458 E:460 ||| .
We  ||| S:460 E:463 ||| PRP
identified  ||| S:463 E:474 ||| VBD
patients  ||| S:474 E:483 ||| NNS
with  ||| S:483 E:488 ||| IN
a  ||| S:488 E:490 ||| DT
new  ||| S:490 E:494 ||| JJ
primary  ||| S:494 E:502 ||| JJ
or  ||| S:502 E:505 ||| CC
secondary  ||| S:505 E:515 ||| JJ
diagnosis  ||| S:515 E:525 ||| NN
of  ||| S:525 E:528 ||| IN
diabetes  ||| S:528 E:537 ||| NN
during  ||| S:537 E:544 ||| IN
a  ||| S:544 E:546 ||| DT
visit  ||| S:546 E:552 ||| NN
( ||| S:552 E:553 ||| -LRB-
baseline  ||| S:553 E:562 ||| NN
visit ||| S:562 E:567 ||| NN
)  ||| S:567 E:569 ||| -RRB-
between  ||| S:569 E:577 ||| IN
January  ||| S:577 E:585 ||| NNP
2005  ||| S:585 E:590 ||| CD
and  ||| S:590 E:594 ||| CC
June  ||| S:594 E:599 ||| NNP
2006  ||| S:599 E:604 ||| CD
at  ||| S:604 E:607 ||| IN
the  ||| S:607 E:611 ||| DT
Queen  ||| S:611 E:617 ||| NNP
Emma  ||| S:617 E:622 ||| NNP
Clinics ||| S:622 E:629 ||| NNP
.  ||| S:629 E:631 ||| .
Each  ||| S:631 E:636 ||| DT
patient ||| S:636 E:643 ||| NN
's  ||| S:643 E:646 ||| POS
medical  ||| S:646 E:654 ||| JJ
record  ||| S:654 E:661 ||| NN
was  ||| S:661 E:665 ||| VBD
reviewed  ||| S:665 E:674 ||| VBN
to  ||| S:674 E:677 ||| TO
obtain  ||| S:677 E:684 ||| VB
demographic  ||| S:684 E:696 ||| JJ
and  ||| S:696 E:700 ||| CC
clinical  ||| S:700 E:709 ||| JJ
information  ||| S:709 E:721 ||| NN
related  ||| S:721 E:729 ||| VBN
to  ||| S:729 E:732 ||| TO
diabetes ||| S:732 E:740 ||| NN
,  ||| S:740 E:742 ||| ,
including  ||| S:742 E:752 ||| VBG
laboratory  ||| S:752 E:763 ||| NN
and  ||| S:763 E:767 ||| CC
test  ||| S:767 E:772 ||| NN
results  ||| S:772 E:780 ||| NNS
and  ||| S:780 E:784 ||| CC
medications ||| S:784 E:795 ||| NN
,  ||| S:795 E:797 ||| ,
from  ||| S:797 E:802 ||| IN
the  ||| S:802 E:806 ||| DT
baseline  ||| S:806 E:815 ||| NN
visit  ||| S:815 E:821 ||| NN
through  ||| S:821 E:829 ||| IN
12  ||| S:829 E:832 ||| CD
months  ||| S:832 E:839 ||| NNS
follow-up ||| S:839 E:848 ||| JJ
.  ||| S:848 E:850 ||| .
Performance  ||| S:850 E:862 ||| NN
indicators  ||| S:862 E:873 ||| NNS
were  ||| S:873 E:878 ||| VBD
selected  ||| S:878 E:887 ||| VBN
from  ||| S:887 E:892 ||| IN
those  ||| S:892 E:898 ||| DT
recommended  ||| S:898 E:910 ||| VBN
by  ||| S:910 E:913 ||| IN
the  ||| S:913 E:917 ||| DT
National  ||| S:917 E:926 ||| NNP
Diabetes  ||| S:926 E:935 ||| NNP
Quality  ||| S:935 E:943 ||| NNP
Improvement  ||| S:943 E:955 ||| NNP
Alliance  ||| S:955 E:964 ||| NNP
and  ||| S:964 E:968 ||| CC
included  ||| S:968 E:977 ||| VBD
selected  ||| S:977 E:986 ||| VBN
8  ||| S:986 E:988 ||| CD
measures ||| S:988 E:996 ||| NNS
:  ||| S:996 E:998 ||| :
1 ||| S:998 E:999 ||| LS
)  ||| S:999 E:1001 ||| -RRB-
Hemoglobin  ||| S:1001 E:1012 ||| NNP
A1c  ||| S:1012 E:1016 ||| NNP
â‰¥9.0 ||| S:1016 E:1020 ||| NNP
% ||| S:1020 E:1021 ||| NN
;  ||| S:1021 E:1023 ||| :
2 ||| S:1023 E:1024 ||| LS
)  ||| S:1024 E:1026 ||| -RRB-
Annual  ||| S:1026 E:1033 ||| JJ
lipid  ||| S:1033 E:1039 ||| JJ
panel  ||| S:1039 E:1045 ||| NN
checked ||| S:1045 E:1052 ||| NNS
;  ||| S:1052 E:1054 ||| :
3 ||| S:1054 E:1055 ||| LS
)  ||| S:1055 E:1057 ||| -RRB-
Systolic  ||| S:1057 E:1066 ||| NNP
blood  ||| S:1066 E:1072 ||| NN
pressure  ||| S:1072 E:1081 ||| NN
< ||| S:1081 E:1082 ||| SYM
140  ||| S:1082 E:1086 ||| CD
mmHg ||| S:1086 E:1090 ||| NN
;  ||| S:1090 E:1092 ||| :
4 ||| S:1092 E:1093 ||| LS
)  ||| S:1093 E:1095 ||| -RRB-
LDL  ||| S:1095 E:1099 ||| NNP
cholesterol  ||| S:1099 E:1111 ||| NN
< ||| S:1111 E:1112 ||| SYM
130  ||| S:1112 E:1116 ||| CD
mg ||| S:1116 E:1118 ||| CD
/ ||| S:1118 E:1119 ||| CD
dL ||| S:1119 E:1121 ||| NN
)  ||| S:1121 E:1123 ||| -RRB-
5 ||| S:1123 E:1124 ||| CD
)  ||| S:1124 E:1126 ||| -RRB-
Annual  ||| S:1126 E:1133 ||| JJ
fundoscopic  ||| S:1133 E:1145 ||| JJ
examination ||| S:1145 E:1156 ||| NN
;  ||| S:1156 E:1158 ||| :
6 ||| S:1158 E:1159 ||| CD
)  ||| S:1159 E:1161 ||| -RRB-
Foot  ||| S:1161 E:1166 ||| NNP
examination ||| S:1166 E:1177 ||| NN
;  ||| S:1177 E:1179 ||| :
7 ||| S:1179 E:1180 ||| CD
)  ||| S:1180 E:1182 ||| -RRB-
Aspirin  ||| S:1182 E:1190 ||| NNP
use ||| S:1190 E:1193 ||| NN
;  ||| S:1193 E:1195 ||| :
8 ||| S:1195 E:1196 ||| CD
)  ||| S:1196 E:1198 ||| -RRB-
Annual  ||| S:1198 E:1205 ||| JJ
evaluation  ||| S:1205 E:1216 ||| NN
for  ||| S:1216 E:1220 ||| IN
urine  ||| S:1220 E:1226 ||| JJ
protein ||| S:1226 E:1233 ||| NN
.  ||| S:1233 E:1235 ||| .
We  ||| S:1235 E:1238 ||| PRP
identified  ||| S:1238 E:1249 ||| VBD
364  ||| S:1249 E:1253 ||| CD
patients ||| S:1253 E:1261 ||| NNS
,  ||| S:1261 E:1263 ||| ,
the  ||| S:1263 E:1267 ||| DT
majority  ||| S:1267 E:1276 ||| NN
Pacific  ||| S:1276 E:1284 ||| NNP
Islanders  ||| S:1284 E:1294 ||| NNPS
( ||| S:1294 E:1295 ||| -LRB-
58 ||| S:1295 E:1297 ||| CD
% ||| S:1297 E:1298 ||| NN
) ||| S:1298 E:1299 ||| -RRB-
,  ||| S:1299 E:1301 ||| ,
with  ||| S:1301 E:1306 ||| IN
Asians  ||| S:1306 E:1313 ||| NNPS
( ||| S:1313 E:1314 ||| -LRB-
15 ||| S:1314 E:1316 ||| CD
% ||| S:1316 E:1317 ||| NN
)  ||| S:1317 E:1319 ||| -RRB-
and  ||| S:1319 E:1323 ||| CC
Native  ||| S:1323 E:1330 ||| NNP
Hawaiians  ||| S:1330 E:1340 ||| NNP
( ||| S:1340 E:1341 ||| -LRB-
17 ||| S:1341 E:1343 ||| CD
% ||| S:1343 E:1344 ||| NN
)  ||| S:1344 E:1346 ||| -RRB-
more  ||| S:1346 E:1351 ||| JJR
frequent  ||| S:1351 E:1360 ||| JJ
than  ||| S:1360 E:1365 ||| IN
Caucasians  ||| S:1365 E:1376 ||| NNP
( ||| S:1376 E:1377 ||| -LRB-
10 ||| S:1377 E:1379 ||| CD
% ||| S:1379 E:1380 ||| NN
) ||| S:1380 E:1381 ||| -RRB-
.  ||| S:1381 E:1383 ||| .
Compared  ||| S:1383 E:1392 ||| VBN
with  ||| S:1392 E:1397 ||| IN
Caucasians ||| S:1397 E:1407 ||| NNP
,  ||| S:1407 E:1409 ||| ,
Native  ||| S:1409 E:1416 ||| NNP
Hawaiians  ||| S:1416 E:1426 ||| NNP
and  ||| S:1426 E:1430 ||| CC
Pacific  ||| S:1430 E:1438 ||| NNP
Islanders  ||| S:1438 E:1448 ||| NNPS
were  ||| S:1448 E:1453 ||| VBD
significantly  ||| S:1453 E:1467 ||| RB
more  ||| S:1467 E:1472 ||| RBR
likely  ||| S:1472 E:1479 ||| JJ
to  ||| S:1479 E:1482 ||| TO
have  ||| S:1482 E:1487 ||| VB
poor  ||| S:1487 E:1492 ||| JJ
glucose  ||| S:1492 E:1500 ||| JJ
control ||| S:1500 E:1507 ||| NN
.  ||| S:1507 E:1509 ||| .
There  ||| S:1509 E:1515 ||| EX
were  ||| S:1515 E:1520 ||| VBD
no  ||| S:1520 E:1523 ||| DT
significant  ||| S:1523 E:1535 ||| JJ
differences  ||| S:1535 E:1547 ||| NNS
between  ||| S:1547 E:1555 ||| IN
groups  ||| S:1555 E:1562 ||| NNS
for  ||| S:1562 E:1566 ||| IN
the  ||| S:1566 E:1570 ||| DT
other  ||| S:1570 E:1576 ||| JJ
measures ||| S:1576 E:1584 ||| NNS
.  ||| S:1584 E:1586 ||| .
Patients  ||| S:1586 E:1595 ||| NNS
compared  ||| S:1595 E:1604 ||| VBN
favorably  ||| S:1604 E:1614 ||| RB
when  ||| S:1614 E:1619 ||| WRB
compared  ||| S:1619 E:1628 ||| VBN
with  ||| S:1628 E:1633 ||| IN
national  ||| S:1633 E:1642 ||| JJ
benchmarks ||| S:1642 E:1652 ||| NNS
.  ||| S:1652 E:1654 ||| .
For  ||| S:1654 E:1658 ||| IN
2  ||| S:1658 E:1660 ||| CD
indicators ||| S:1660 E:1670 ||| NNS
,  ||| S:1670 E:1672 ||| ,
adherence  ||| S:1672 E:1682 ||| NN
was  ||| S:1682 E:1686 ||| VBD
significantly  ||| S:1686 E:1700 ||| RB
higher  ||| S:1700 E:1707 ||| JJR
for  ||| S:1707 E:1711 ||| IN
the  ||| S:1711 E:1715 ||| DT
total  ||| S:1715 E:1721 ||| JJ
study  ||| S:1721 E:1727 ||| NN
population  ||| S:1727 E:1738 ||| NN
compared  ||| S:1738 E:1747 ||| VBN
with  ||| S:1747 E:1752 ||| IN
the  ||| S:1752 E:1756 ||| DT
US  ||| S:1756 E:1759 ||| NNP
average  ||| S:1759 E:1767 ||| NN
( ||| S:1767 E:1768 ||| -LRB-
systolic  ||| S:1768 E:1777 ||| JJ
blood  ||| S:1777 E:1783 ||| NN
pressure  ||| S:1783 E:1792 ||| NN
< ||| S:1792 E:1793 ||| SYM
140  ||| S:1793 E:1797 ||| CD
mmHg ||| S:1797 E:1801 ||| NN
,  ||| S:1801 E:1803 ||| ,
aspirin  ||| S:1803 E:1811 ||| JJ
therapy ||| S:1811 E:1818 ||| NN
) ||| S:1818 E:1819 ||| -RRB-
.  ||| S:1819 E:1821 ||| .
For  ||| S:1821 E:1825 ||| IN
2  ||| S:1825 E:1827 ||| CD
indicators ||| S:1827 E:1837 ||| NNS
,  ||| S:1837 E:1839 ||| ,
there  ||| S:1839 E:1845 ||| EX
were  ||| S:1845 E:1850 ||| VBD
no  ||| S:1850 E:1853 ||| DT
significant  ||| S:1853 E:1865 ||| JJ
difference  ||| S:1865 E:1876 ||| NN
( ||| S:1876 E:1877 ||| -LRB-
LDL  ||| S:1877 E:1881 ||| NNP
cholesterol  ||| S:1881 E:1893 ||| NN
< ||| S:1893 E:1894 ||| SYM
130  ||| S:1894 E:1898 ||| CD
mg ||| S:1898 E:1900 ||| CD
/ ||| S:1900 E:1901 ||| CD
dL ||| S:1901 E:1903 ||| NN
,  ||| S:1903 E:1905 ||| ,
annual  ||| S:1905 E:1912 ||| JJ
foot  ||| S:1912 E:1917 ||| NN
exam ||| S:1917 E:1921 ||| NN
)  ||| S:1921 E:1923 ||| -RRB-
and  ||| S:1923 E:1927 ||| CC
for  ||| S:1927 E:1931 ||| IN
2  ||| S:1931 E:1933 ||| CD
indicators ||| S:1933 E:1943 ||| NNS
,  ||| S:1943 E:1945 ||| ,
adherence  ||| S:1945 E:1955 ||| NN
was  ||| S:1955 E:1959 ||| VBD
significantly  ||| S:1959 E:1973 ||| RB
lower  ||| S:1973 E:1979 ||| JJR
for  ||| S:1979 E:1983 ||| IN
the  ||| S:1983 E:1987 ||| DT
study  ||| S:1987 E:1993 ||| NN
population  ||| S:1993 E:2004 ||| NN
( ||| S:2004 E:2005 ||| -LRB-
hemoglobin  ||| S:2005 E:2016 ||| CD
A1c  ||| S:2016 E:2020 ||| CD
> ||| S:2020 E:2021 ||| CD
9 ||| S:2021 E:2022 ||| CD
% ||| S:2022 E:2023 ||| NN
,  ||| S:2023 E:2025 ||| ,
annual  ||| S:2025 E:2032 ||| JJ
fundoscopic  ||| S:2032 E:2044 ||| JJ
examination ||| S:2044 E:2055 ||| NN
) ||| S:2055 E:2056 ||| -RRB-
.  ||| S:2056 E:2058 ||| .
Native  ||| S:2058 E:2065 ||| NNP
Hawaiians  ||| S:2065 E:2075 ||| NNP
and  ||| S:2075 E:2079 ||| CC
Pacific  ||| S:2079 E:2087 ||| NNP
Islanders  ||| S:2087 E:2097 ||| NNPS
with  ||| S:2097 E:2102 ||| IN
diabetes  ||| S:2102 E:2111 ||| NNS
have  ||| S:2111 E:2116 ||| VBP
poorer  ||| S:2116 E:2123 ||| JJR
blood  ||| S:2123 E:2129 ||| NN
glucose  ||| S:2129 E:2137 ||| NNS
control  ||| S:2137 E:2145 ||| VBP
compared  ||| S:2145 E:2154 ||| VBN
with  ||| S:2154 E:2159 ||| IN
Caucasians  ||| S:2159 E:2170 ||| NNP
and  ||| S:2170 E:2174 ||| CC
Asians ||| S:2174 E:2180 ||| NNPS
,  ||| S:2180 E:2182 ||| ,
but  ||| S:2182 E:2186 ||| CC
the  ||| S:2186 E:2190 ||| DT
overall  ||| S:2190 E:2198 ||| JJ
care  ||| S:2198 E:2203 ||| NN
is  ||| S:2203 E:2206 ||| VBZ
otherwise  ||| S:2206 E:2216 ||| RB
generally  ||| S:2216 E:2226 ||| RB
similar ||| S:2226 E:2233 ||| JJ
.  ||| S:2233 E:2235 ||| .
The  ||| S:2235 E:2239 ||| DT
diabetes  ||| S:2239 E:2248 ||| NN
care  ||| S:2248 E:2253 ||| NN
received  ||| S:2253 E:2262 ||| VBD
by  ||| S:2262 E:2265 ||| IN
patients  ||| S:2265 E:2274 ||| NNS
in  ||| S:2274 E:2277 ||| IN
this  ||| S:2277 E:2282 ||| DT
clinic  ||| S:2282 E:2289 ||| NN
that  ||| S:2289 E:2294 ||| WDT
treats  ||| S:2294 E:2301 ||| VBZ
a  ||| S:2301 E:2303 ||| DT
generally  ||| S:2303 E:2313 ||| RB
underserved  ||| S:2313 E:2325 ||| JJ
population  ||| S:2325 E:2336 ||| NN
compares  ||| S:2336 E:2345 ||| VBZ
favorably  ||| S:2345 E:2355 ||| RB
with  ||| S:2355 E:2360 ||| IN
national  ||| S:2360 E:2369 ||| JJ
benchmarks ||| S:2369 E:2379 ||| NNS
.  ||| S:2379 E:2381 ||| .
